OTX 008
Alternative Names: OTX-008; PTX-008Latest Information Update: 29 Jan 2022
At a glance
- Originator PepTx
- Developer OncoEthix
- Class Antineoplastics; Calixarenes; Small molecules
- Mechanism of Action Galectin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 11 Dec 2021 Pharmacodynamics data from a preclinical trial in chronic lymphocytic leukemia presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in Belgium (SC)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in France (SC)